Tecovirimat Oral Capsule + Placebo for Tecovirimat + Tecovirimat Oral Capsule (Open Label)
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Tecovirimat Oral Capsule + Placebo for Tecovirimat + Tecovirimat Oral Capsule (Open Label)
Tecovirimat Oral Capsule + Placebo for Tecovirimat + Tecovirimat Oral Capsule (Open Label) is a phase 3 stage product being developed by SIGA Technologies for MPOX. The current trial status is terminated. This product is registered under clinical trial identifier NCT05534984. Target conditions include MPOX.
What happened to similar drugs?
0 of 1 similar drugs in MPOX were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05534984 | Phase 3 | Terminated |
Competing Products
5 competing products in MPOX
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1769 | Moderna | Phase 2 | 0 |
| BNT166a | BioNTech | Phase 2 | 39 |
| MVA-BN | Bavarian Nordic | Phase 2 | 36 |
| MVA-BN standard regimen + MVA-BN half-dose regimen | Bavarian Nordic | Phase 3 | 44 |
| Jynneos + MVA-BN (Quail) | Bavarian Nordic | Phase 2 | 39 |